From The Neuroscience Research Unit and the Mind and Brain Studies Initiative (Tayeb), Division of Neurology, Department of Internal Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, from the Department of neurology (Khallaf), Neuroscience Center, King Fahad Specialist Hospital Dammam, from Neurology Unit (Muayqil), from the the Department of Medicine (Alkeridy), College of Medicine, King Saud University, Riyadh, from the Neurology Division (Alibrahim), Department of Medicine, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, from the Department of Neurology (Alfaify), Prince Sultan Military Medical City, from the Neuroscience Centre (Qadi), King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia, and from the Department of Psychiatry and Neuroscience (Tarazi), Harvard Medical School and McLean Hospital, Belmont, USA.
Neurosciences (Riyadh). 2023 Apr;28(2):77-84. doi: 10.17712/nsj.2023.2.20220133.
Alzheimer Disease (AD) constitutes a major global healthcare problem. Standard AD pharmacotherapies offer only modest transient cognitive and behavioral benefits. Aducanumab, an amyloid monoclonal antibody, was the first disease modifying agent to be approved for AD treatment. However, concerns about its efficacy and side effects led regulatory institutions around the world to restrict its use. Lecanemab was the second amyloid antibody to receive accelerated approval for use in early AD. This review and consensus statement was prepared by the Saudi Chapter of Cognitive and Behavioral Neurology to review the current developments in AD immunotherapies from a Saudi perspective. We outline recommendations with regards to offering aducanumab and other future immunotherapies to Saudi AD patients. We describe resources, infrastructure, research, and clinical practice changes that must be attained to transform the patient journey and clinical pathways of AD in Saudi Arabia to enable offering AD immunotherapies in Saudi Arabia.
阿尔茨海默病（AD）是一个全球性的主要医疗保健问题。标准的 AD 药物治疗仅提供适度的短暂认知和行为益处。阿杜卡努单抗，一种淀粉样单克隆抗体，是第一个被批准用于 AD 治疗的疾病修饰药物。然而，对其疗效和副作用的担忧导致世界各地的监管机构限制了其使用。仑卡奈单抗是第二个获得加速批准用于早期 AD 的淀粉样蛋白抗体。本综述和共识声明由沙特认知和行为神经病学分会编写，旨在从沙特阿拉伯的角度审查 AD 免疫疗法的最新进展。我们提出了关于向沙特 AD 患者提供阿杜卡努单抗和其他未来免疫疗法的建议。我们描述了必须实现的资源、基础设施、研究和临床实践的改变，以改变沙特阿拉伯 AD 患者的治疗途径和临床路径，从而能够在沙特阿拉伯提供 AD 免疫疗法。
